Physician profile
Wayne Woo
NPI 1023064177
$30,117.22
in general payments reported to CMS, 2019-2025
54 companies · $3,635 in 2025
The $3,635 reported for 2025 was more than what 85% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,286 · 2020: $4,981 · 2021: $4,751 · 2022: $3,700 · 2023: $3,597 · 2024: $3,168 · 2025: $3,635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $39.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,359.90 |
| Education | $39.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,191.35 | 2019-2025 | Freestyle Libre, Freestyle Libre 3, Proclaim |
| Novo Nordisk INC | $3,677.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Tandem Diabetes Care, INC. | $2,700.67 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $2,315.43 | 2019-2025 | Evenity, Prolia, Tepezza |
| Lilly USA, LLC | $2,181.72 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals Lp | $1,881.83 | 2019-2023 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,326.03 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $1,172.74 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $1,119.25 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $989.64 | 2019-2023 | Cycloset |
| Abbvie INC. | $932.36 | 2019-2025 | Synthroid |
| Merck Sharp & Dohme LLC | $918.84 | 2019-2023 | Steglatro, Segluromet, Steglujan |
| Amarin Pharma, INC. | $680.21 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $632.37 | 2021-2025 | |
| Radius Health, INC. | $611.50 | 2019-2024 |
Show all 54 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $604.68 | 2019-2025 | Dexcom G6 Transmitter |
| Corcept Therapeutics | $564.02 | 2019-2025 | Korlym |
| Beta Bionics, INC. | $525.42 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Ibsa Pharma INC. | $288.18 | 2019-2025 | Licart, Tirosint, Flector |
| Amneal Pharmaceuticals LLC | $202.36 | 2020-2024 | Unithroid |
| Arbor Pharmaceuticals, INC. | $198.25 | 2019-2021 | |
| Tolmar, INC. | $193.85 | 2024-2025 | Jatenzo |
| Esperion Therapeutics, INC. | $181.98 | 2020-2024 | Nexletol |
| Valeritas, INC. | $168.93 | 2019 | |
| Recordati_rare_diseases_inc. | $150.82 | 2020-2023 | Signifor Lar, Isturisa |
| Madrigal Pharmaceuticals | $144.30 | 2025 | Rezdiffra |
| Nestle Healthcare Nutrition INC. | $143.00 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $141.37 | 2019-2022 | |
| Glaxosmithkline, LLC. | $136.47 | 2025 | Arexvy, Shingrix |
| Xeris Pharmaceuticals, INC. | $121.35 | 2022-2024 | Gvoke Hypopen |
| Roche Diabetes Care, INC. | $111.98 | 2019 | |
| Shire North American Group INC | $102.35 | 2019 | |
| Neurocrine Biosciences, INC. | $88.63 | 2024-2025 | |
| Bard Peripheral Vascular, INC. | $68.41 | 2024 | Rotarexs 6 F X 135 Cm |
| Embecta Corp. | $59.23 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Lifescan, INC. | $57.38 | 2021-2022 | |
| Eusa Pharma (US) LLC | $55.38 | 2022 | |
| Ascendis Pharma Endocrinology INC | $52.60 | 2024-2025 | Yorvipath |
| Acerus Pharmaceuticals Corporation | $50.18 | 2022 | |
| Cequr Corporation | $46.58 | 2024 | Cequr Simplicity |
| Medtronic, INC. | $42.54 | 2022-2025 | Minimed 780g |
| Alexion Pharmaceuticals, INC. | $39.91 | 2019-2025 | Strensiq |
| Halozyme INC | $33.46 | 2023 | |
| Amryt Pharma Holdings Ltd | $30.65 | 2021-2023 | Mycapssa |
| Insulet Corporation | $29.60 | 2025 | Omnipod |
| Antares Pharma, INC. | $22.89 | 2024 | Xyosted |
| Sequel Med Tech, LLC | $21.97 | 2025 | Twiist |
| Pfizer INC. | $20.02 | 2023 | |
| Medtronic Minimed, INC. | $16.35 | 2019 | |
| Vifor Pharma, INC. | $15.57 | 2019 | |
| Ascensia Diabetes Care US INC. | $15.29 | 2024 | |
| Grt US Holding, INC. | $14.03 | 2021 | |
| Becton, Dickinson and Company | $12.91 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $12.84 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wayne Woo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.